Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$923,350
+$124,920 QoQ
Shares Held
36,875
+21.6% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 50%
Shared 50%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026TUDOR INVESTMENT CORP ET AL holds $333,275,952 across 117 Biotechnology names. ZYME ranks #54 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
462,588 | $53,114,354 | |
| 2 | RPRX |
Royalty Pharma plc
|
671,680 | $32,220,489 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
495,591 | $28,818,616 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
650,000 | $26,149,500 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
267,520 | $14,103,654 | |
| 6 | FOLD |
AMICUS THERAPEUTICS, INC.
|
900,000 | $13,014,000 | |
| 7 | ABVX |
Abivax S.A.
|
101,611 | $11,314,384 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
87,852 | $8,543,607 |
All Filings in ZYME
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $923,350 | 36,875 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $798,430 | 30,324 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $641,917 | 37,583 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $430,377 | 34,293 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||